Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
361
datasets available to search
ShareScore release 0.9.0
Dataset results
361 results for “psoriatic arthritis”
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
ClinicalTrials.gov study NCT02798211. IPD Sharing: UNDECIDED. Countries: 2. Publications: 1.
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
ClinicalTrials.gov study NCT02662985. IPD Sharing: UNDECIDED. Countries: 17. Publications: 1.
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
ClinicalTrials.gov study NCT01989468. IPD Sharing: UNDECIDED. Countries: 13. Publications: 5.
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheum
ClinicalTrials.gov study NCT03675308. IPD Sharing: YES. Countries: 39. Publications: 9.
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
ClinicalTrials.gov study NCT02294227. IPD Sharing: UNDECIDED. Countries: 13. Publications: 3.
Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
ClinicalTrials.gov study NCT02721966. IPD Sharing: UNDECIDED. Countries: 18. Publications: 2.
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
ClinicalTrials.gov study NCT02404350. IPD Sharing: UNDECIDED. Countries: 28. Publications: 6.
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
ClinicalTrials.gov study NCT03671148. IPD Sharing: YES. Countries: 25. Publications: 9.
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
ClinicalTrials.gov study NCT02745080. IPD Sharing: YES. Countries: 26. Publications: 2.
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
ClinicalTrials.gov study NCT03031782. IPD Sharing: UNDECIDED. Countries: 10. Publications: 2.
Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
ClinicalTrials.gov study NCT02771210. IPD Sharing: UNDECIDED. Countries: 8. Publications: 3.
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
ClinicalTrials.gov study NCT01892436. IPD Sharing: UNDECIDED. Countries: 18. Publications: 1.
Psoriatic arthritis disease subtypes are phenocopied in a novel humanized murine model of psoriasis and joint inflammation
<p><em><span>Data processing and analysis</span></em></p> <p><span>Data normalization, quality control, and analysis was conducted by the UPMC Hillman Cancer Bioinformatics Services. Following the GeoMX NGS pipeline (<span>sequencing saturation 92%±0.12% (mean±S.E.M)), t</span>he resulting read count matrix was passed through robust QC procedure to remove ROIs of low surface area (<5000 µm<sup>2</sup>) or low perfect aligned reads (<80%), and probes of low quality or identified as global or local outliers (fails Grubbs outlier test in ≥ 20% segments). The remaining data were back-ground subtracted and Q3 normalized to house-keeping genes. ROIs were considered positive for CD8 T cells if their CD8 memory T cell deconvolution fraction was > 0 (R, spatialDecon, CellProfileLibrary; Human Adult ImmuneTumor_safeTME profile). Genes differentially expressed between groups of interest were detected using gene-wise linear modeling in R (edgeR, limma v3.50.3), with p-value adjusted for false discovery rate. Contrasts of groups were performed using t-tests at a significance level of 0.05.</span></p>
A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis
ClinicalTrials.gov study NCT02969525. IPD Sharing: Not stated. Countries: 6. Publications: 3.
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
ClinicalTrials.gov study NCT03747939. IPD Sharing: YES. Countries: 11. Publications: 1.
The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
ClinicalTrials.gov study NCT01818804. IPD Sharing: YES. Countries: 1. Publications: 2.
Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients
ClinicalTrials.gov study NCT02065713. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
ClinicalTrials.gov study NCT01976364. IPD Sharing: YES. Countries: 16. Publications: 13.
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
ClinicalTrials.gov study NCT01212770. IPD Sharing: YES. Countries: 16. Publications: 6.
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Art
ClinicalTrials.gov study NCT04527380. IPD Sharing: YES. Countries: 12. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.